Renee Hart, BS LumaCyte United States Picture a familiar scenario: a promising cell therapy program advances through early clinical development on the strength of a phenotypic marker panel and a release assay that was never meant to do more than confirm identity. Then comes the process...
CHARLOTTESVILLE, VA – June 02, 2026 – The frontier of modern medicine is not a pill; it is a living cell, reprogrammed and redeployed to fight our most intractable diseases. From cancer to genetic disorders, cell and gene therapies represent a paradigm shift in treatment. Yet, behind the...
Developed by the ISCT Cold Chain Management and Logistics Working Group and the ISCT Process Development and Manufacturing Committee Introduction Cryopreservation is central to the manufacturing, distribution, and clinical delivery of cell and gene therapy products. Freezing enables...
On behalf of the Business Development & Finance Committee The cell and gene therapy (CGT) industry continues to evolve rapidly, with investment activity providing an important window into where investors and biopharma companies see future opportunity. As part of its quarterly market...
Developed by the ISCT Business Development and Finance (BDF) Committee Q1 2026 was the most active quarter for CGT investment recorded in this series with aggregate disclosed deal value significantly exceeding any quarter in 2025. Twenty-two disclosed transactions are covered in this...
1 Comment - no search term matches found in comments.
Leanne Kodsmann Director of Market Development Cryoport Systems United States There’s an assumption that still shows up in how scale is discussed across advanced therapies, even if it’s rarely stated outright. Once a program proves itself clinically, scale is expected to follow a...
Developed by ISCT Business Development & Finance Committee The year 2025 marked a notable period of momentum for the cell and gene therapy (CGT) sector, characterised by significant deal making across multiple therapeutic modalities. In 2025, the field saw approximately USD 12 billion...
Introduction In the rapidly evolving landscape of advanced therapies, few challenges are as complex — or as consequential — as scaling cell therapy manufacturing to meet growing clinical and commercial demand. In this expert analysis, the team at AGC Biologics shares their perspective on...
Advanced therapy development is no longer limited by whether the science can work. Platform technologies are established, translational pathways are better understood, and the distance between discovery and first-in-human continues to shrink. What now limits progress for many programs is the...
By the ISCT Business Development & Finance Committee With investment activity fluctuating across the cell and gene therapy sector, access to timely financing and M&A insights is essential for organizations to stay informed and ahead of the curve. The ISCT Business Development &...